Radiotherapy for Extracranial Oligometastatic Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2026

Conditions
Breast Cancer Metastatic
Interventions
DRUG

standard of care

patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.

RADIATION

radiotherapy + standard of care

"Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist."

Trial Locations (2)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Unknown

RECRUITING

Wei-Fang Yang, Taizhou

All Listed Sponsors
collaborator

Liaoning Cancer Hospital & Institute

OTHER

collaborator

Wuhan University

OTHER

collaborator

China-Japan Union Hospital, Jilin University

OTHER

collaborator

Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

OTHER

collaborator

West China Hospital

OTHER

collaborator

Shanxi Province Cancer Hospital

OTHER

collaborator

Peking Union Medical College Hospital

OTHER

lead

Chinese Academy of Medical Sciences

OTHER